Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 7:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Convulsions Clear all
Recruiting Phase 1Phase 2 Interventional

A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy

NCT06388707
View directory record Official record
Conditions
Drug Resistant Epilepsy, Epilepsy, Seizures, Focal, Seizure, Seizure Disorder
Interventions
NaviFUS System
Device
Lead sponsor
NaviFUS Corporation
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Palo Alto, California • Boston, Massachusetts • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 16, 2026, 7:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dexmedetomidine in Seizure Patients

NCT01116700
View directory record Official record
Conditions
Seizure Disorders
Interventions
Dexmedetomidine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 8, 2013 · Synced Sep 16, 2026, 7:08 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dosing of Levetiracetam (Keppra) in Neonates

NCT01239212
View directory record Official record
Conditions
Seizures
Interventions
levetiracetam
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Day to 30 Days
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2021 · Synced Sep 16, 2026, 7:08 PM EDT
Completed Phase 1 Interventional Results available

University of Alabama at Birmingham (UAB) Pediatric CBD Program

NCT02695537
View directory record Official record
Conditions
Epilepsy, Seizures
Interventions
Epidiolex
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Year to 19 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Sep 16, 2026, 7:08 PM EDT
Completed No phase listed Observational

Transcranial Magnetic Stimulation for the Treatment of Poorly Controlled Partial Epilepsy

NCT00001666
View directory record Official record
Conditions
Partial Epilepsy, Seizures
Interventions
Cadwell High-Speed Magnetoelectric Stimulator, Magpro High-Speed Magnetoelectric Stimulator
Device
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 16, 2026, 7:08 PM EDT
Completed Not applicable Interventional

EpiWatch: Evaluation of a Non-EEG Physiological Signal Based Seizure Monitoring System

NCT05059002
View directory record Official record
Conditions
Epilepsy, Tonic-Clonic
Interventions
Physiological signal monitoring and seizure detection
Device
Lead sponsor
EpiWatch, Inc.
Industry
Eligibility
5 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 16, 2026, 7:08 PM EDT
Terminated Phase 3 Interventional Results available

Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

NCT00448539
View directory record Official record
Conditions
Refractory Partial Onset Seizures
Interventions
Rufinamide
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 80 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
27
States / cities
Mobile, Alabama • Little Rock, Arkansas • Bradenton, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Sep 16, 2026, 7:08 PM EDT
Completed Phase 3 Interventional Results available

Extension Study Of Long-Term Safety And Efficacy Of Pregabalin As Monotherapy (Lyrica) In Patients With Partial Seizures

NCT00596466
View directory record Official record
Conditions
Epilepsy
Interventions
pregabalin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
34
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Fullerton, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Sep 16, 2026, 7:08 PM EDT
Recruiting Phase 3 Interventional

A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures

NCT04715646
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
1 Month and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
2
States / cities
Hawthorne, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 16, 2026, 7:08 PM EDT
Completed Not applicable Interventional Results available

North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2

NCT03548779
View directory record Official record
Conditions
Epilepsy; Seizure, Neuromuscular Diseases, Brain Malformation, Intellectual Disability, Autism Spectrum Disorder, Hypotonia, Inborn Errors of Metabolism, Movement Disorders, Genetic Disease, Development Delay, Chromosome Abnormality, Hearing Loss, Dysmorphic Features, Skeletal Dysplasia, Congenital Abnormality, Microcephaly, Macrocephaly
Interventions
Pre-visit prep, usual care + exome seq
Behavioral · Diagnostic Test
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
0 Years and older
Enrollment
548 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
Asheville, North Carolina • Chapel Hill, North Carolina • Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Sep 16, 2026, 7:08 PM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

NCT02224690
View directory record Official record
Conditions
Epilepsy, Lennox-Gastaut Syndrome
Interventions
GWP42003-P 20 mg/kg/day Dose, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 55 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
17
States / cities
Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 16, 2026, 7:08 PM EDT
Recruiting No phase listed Observational

FITting Non-invasive Tests in Lynch Syndrome Surveillance

NCT06898996
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Fecal immunochemical test
Other
Lead sponsor
University of Chicago
Other
Eligibility
20 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Chicago, Illinois • Ann Arbor, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 16, 2026, 7:08 PM EDT
Terminated Not applicable Interventional

Evaluating Dietary Intervention Before surgicaL Treatment for Epilepsy

NCT02261753
View directory record Official record
Conditions
Cortical Dysplasia
Interventions
Classical ketogenic diet
Dietary Supplement
Lead sponsor
University College, London
Other
Eligibility
3 Years to 15 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Sep 16, 2026, 7:08 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes

NCT00384956
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Azacitidine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 11, 2016 · Synced Sep 16, 2026, 7:08 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Month to Less Than 18 Years Old With Epilepsy Syndromes Associated With Generalized Seizures.

NCT01969851
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
1 Month to 18 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Los Angeles, California • Orlando, Florida • Henderson, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Sep 16, 2026, 7:08 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Criteria for Advanced Prosthetic Foot Prescription

NCT03505983
View directory record Official record
Conditions
Prosthesis User, Amputation; Traumatic, Limb, Lower
Interventions
ESR Prosthetic Foot First, Articulating ESR Prosthetic Foot First, Powered Prosthetic Foot First
Device
Lead sponsor
VA New York Harbor Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 16, 2026, 7:08 PM EDT
Completed Phase 4 Interventional

Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Chronic-Dose 4-Period Replicate Design

NCT01713777
View directory record Official record
Conditions
Epilepsy
Interventions
Lamotrigine Generic "A", Lamotrigine generic "B"
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
8
States / cities
Birmingham, Alabama • Des Moines, Iowa • Kansas City, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2015 · Synced Sep 16, 2026, 7:08 PM EDT
Completed No phase listed Observational

Phenotype and Etiology of Pallister-Hall Syndrome

NCT00001404
View directory record Official record
Conditions
Malformations, Multiple Abnormalies, Polydactyly
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
1,170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2016
U.S. locations
3
States / cities
Los Angeles, California • Bethesda, Maryland • Greenwood, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 15, 2019 · Synced Sep 16, 2026, 7:08 PM EDT
Completed No phase listed Observational

Putting Electroencephalography (EEG) in the Emergency Department

NCT01355211
View directory record Official record
Conditions
Altered Mental Status, Generalized Nonconvulsive Seizure Disorder, Status-epilepticus
Interventions
Not listed
Lead sponsor
Bio-Signal Group Corp.
Industry
Eligibility
13 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2012 · Synced Sep 16, 2026, 7:08 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

P-glycoprotein Inhibition as Adjunct Treatment for Medically Refractory Epilepsy.

NCT00524134
View directory record Official record
Conditions
Epilepsy
Interventions
Carvedilol-CR
Drug
Lead sponsor
Columbia University
Other
Eligibility
10 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2016 · Synced Sep 16, 2026, 7:08 PM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Cholinergic Enhancement of Theta

NCT07228338
View directory record Official record
Conditions
Epilepsy, Seizures, Cognitive Impairment, Mild, Memory Disorder, Memory Loss
Interventions
COBENFY KarXT (50/20 mg), Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 16, 2026, 7:08 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures

NCT02408549
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide Tablet, Lacosamide Oral Solution
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
4 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
16
States / cities
Little Rock, Arkansas • Santa Monica, California • Colorado Springs, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Sep 16, 2026, 7:08 PM EDT
Completed Phase 3 Interventional Results available

Add on Lacosamide Versus High Dose Monotherapy

NCT01345058
View directory record Official record
Conditions
Epilepsy
Interventions
lacosamide, levetiracetam
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 16, 2026, 7:08 PM EDT
Completed Phase 3 Interventional

A Study for Treatment of Partial Seizures in Children

NCT00102713
View directory record Official record
Conditions
Partial Seizures
Interventions
Divalproex Sodium (Depakote Sprinkle Capsules)
Drug
Lead sponsor
Abbott
Industry
Eligibility
3 Years to 10 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
10
States / cities
Northport, Alabama • Phoenix, Arizona • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 20, 2007 · Synced Sep 16, 2026, 7:08 PM EDT